In short
TranspoCART19 is an innovative cell therapy being studied in a Phase I/IIa clinical trial for patients with relapsed or refractory B-cell lymphoma. This trial aims to evaluate the safety, determine the optimal dose, and assess the effectiveness of TranspoCART19 cells in treating this challenging form of cancer. The study involves genetically modifying patients' own T lymphocytes to target CD19, a protein found on B-cell lymphomas, potentially offering a new treatment option for those who have not responded to previous therapies.
At a glance
- Trial Name
- Phase I/IIa study of TranspoCART19 infusion for relapsed or refractory B-cell lymphoma
- Treatment
- TranspoCART19 (genetically modified autologous T lymphocytes)
- Target Condition
- Relapsed or refractory B-cell lymphoma
- Main Objectives
- Evaluate safety, determine optimal dose, assess efficacy
- Key Eligibility
- Age 18-80, specific B-cell lymphoma types, failed previous treatments
- Administration
- Intravenous infusion of cell suspension
- Primary Endpoints
- Safety assessment, maximum tolerated dose, response rate at 3 months
- Secondary Endpoints
- Duration of response, survival rates, quality of life, biomarker identification
What is TRANSPOCART19?
TRANSPOCART19 is an innovative medical treatment being studied for patients with relapsed or refractory B-cell lymphoma. This means it's designed for people whose lymphoma has either come back after initial treatment or hasn't responded well to previous treatments.
TRANSPOCART19 is classified as a cell therapy, which is a type of treatment where a patient's own cells are modified to fight their disease. Specifically, it's considered an advanced therapy that uses genetically modified T lymphocytes (a type of white blood cell) to target cancer cells.
How Does TRANSPOCART19 Work?
TRANSPOCART19 works by using a patient's own T cells, which are an important part of the immune system. Here's a simplified explanation of the process:
- T cells are collected from the patient's blood through a process called lymphapheresis.
- These cells are then genetically modified in a laboratory using a system called Sleeping Beauty transposon.
- The modification gives the T cells the ability to recognize and attack cancer cells that have a specific marker called CD19 on their surface.
- The modified cells, now called TRANSPOCART19, are then given back to the patient through an intravenous infusion (a drip into a vein).
Once in the body, these modified T cells can potentially seek out and destroy cancer cells that have the CD19 marker, which is commonly found on B-cell lymphomas.
Who Can Receive TRANSPOCART19?
TRANSPOCART19 is being studied for patients with several types of B-cell lymphomas that have not responded well to other treatments. These include:
- Diffuse large B-cell lymphoma that has relapsed or not responded after at least two other treatments
- Primary diffuse large B-cell CNS lymphoma that has not responded to or has come back after treatment
- Mantle cell lymphoma that has not responded to at least one previous treatment
- Follicular lymphoma (grades 1, 2, or 3a) that has not responded to at least two previous treatments
- Marginal zone lymphoma that has not responded to at least two previous treatments
Patients must be between 18 and 80 years old and meet certain health criteria to be eligible for the study.
Clinical Trial Objectives
The ongoing clinical trial for TRANSPOCART19 has several important goals:
- To determine if TRANSPOCART19 is safe to use in patients
- To find the right dose of TRANSPOCART19 that can be effective without causing too many side effects
- To see how well TRANSPOCART19 works in treating B-cell lymphomas
- To understand how long the treatment effects last
- To study how long the modified T cells stay in the patient's body
- To assess the impact of the treatment on patients' quality of life
The trial is divided into two phases. Phase I focuses on safety and finding the right dose, while Phase II looks at how effective the treatment is.
Potential Benefits
If successful, TRANSPOCART19 could offer several potential benefits for patients with hard-to-treat B-cell lymphomas:
- A new treatment option for patients who have not responded to other therapies
- Possibility of achieving remission (when cancer signs and symptoms decrease or disappear)
- Potential for longer survival without the cancer progressing
- A personalized approach using the patient's own immune cells
However, it's important to remember that these potential benefits are still being studied and are not guaranteed.
Possible Side Effects
As with any new treatment, TRANSPOCART19 may cause side effects. The clinical trial is carefully monitoring for:
- Cytokine release syndrome (CRS): A condition where the immune system becomes overactive, potentially causing fever, low blood pressure, and other symptoms
- Neurological toxicity: Side effects that affect the nervous system
- Other adverse events, particularly those that are severe (grade III or IV)
The study will closely track any side effects in the first month after treatment and continue monitoring for up to two years.
Quality of Life Considerations
An important aspect of the TRANSPOCART19 study is assessing how the treatment affects patients' overall quality of life. Participants will be asked to complete questionnaires before treatment, and then at 3 months, 6 months, and one year after receiving TRANSPOCART19. This information will help researchers understand not just how effective the treatment is at fighting cancer, but also how it impacts patients' daily lives and well-being.